Compounded Tirzepatide: What It Is, Whether It Is Safe and Legal, and What It Costs in 2026
Compounded tirzepatide is made by a licensed pharmacy for one patient at a time. It is not FDA-approved. Here is what the FDA has said, how to vet a pharmacy and prescriber, and what you should expect to pay.
Compounded tirzepatide is a version of the weight-loss and diabetes medicine tirzepatide that a licensed pharmacy mixes for an individual patient with a prescription. It is not FDA-approved, so the FDA does not check it for safety, effectiveness or quality before it is sold. Since the FDA declared the tirzepatide shortage over in December 2024, a state-licensed pharmacy can still compound it for a specific patient when the prescriber documents a clinical reason, but you should vet both the pharmacy and the prescriber carefully.
- Compounded tirzepatide is not FDA-approved and is not the same as any brand-name medication.
- The FDA declared the tirzepatide injection shortage resolved on December 19, 2024.
- State-licensed (503A) pharmacies may still compound it from an individual prescription when a prescriber documents a significant difference the patient needs.
- As of May 31, 2026, the FDA had received more than 730 adverse event reports linked to compounded tirzepatide.
- Always use a U.S. state-licensed pharmacy and a real prescriber. Never buy "research use only" products.
What compounded tirzepatide is
Tirzepatide is a once-weekly injection that acts on two gut hormone receptors, GIP and GLP-1. It lowers appetite, slows how fast the stomach empties and helps control blood sugar. You can read more in our guide to what tirzepatide is and how it works.
Compounding means a licensed pharmacist prepares a medicine for a specific patient, starting from the raw active ingredient. A compounded tirzepatide vial is made by that pharmacy, not by the drug's original manufacturer.
That has one big consequence. The FDA says compounded drugs are not FDA-approved, so the agency does not review them for safety, effectiveness or quality before they are sold. The FDA also says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.
The clinical trials that showed tirzepatide's results used the FDA-approved product, not compounded versions. In the SURMOUNT-1 trial of 2,539 adults with obesity or overweight and no diabetes, people on the 15 mg weekly dose lost an average of 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo (NEJM, 2022). A compounded product may or may not perform the same way, because no one has tested it in those trials.
503A pharmacies vs 503B outsourcing facilities
Federal law has two paths for compounding. They are named after sections of the Federal Food, Drug, and Cosmetic Act.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A state-licensed pharmacy or physician | A facility registered with the FDA as an outsourcing facility |
| Prescription | Needs a valid prescription for an individual patient | Can fill patient prescriptions or bulk orders from providers |
| Main oversight | State boards of pharmacy | FDA, with inspections on a risk-based schedule |
| Manufacturing standard | Exempt from federal good manufacturing practice (CGMP) rules | Must follow CGMP rules |
| Adverse event reporting to FDA | Not required | Required |
| Tirzepatide in 2026 | Patient-specific compounding with a documented clinical need | Tirzepatide is not on the 503B bulks list; FDA proposed in April 2026 to formally exclude it |
Most compounded tirzepatide sold to patients in 2026 comes from 503A pharmacies. Being registered as a 503B facility is not an FDA approval. The FDA says registration only means it received the required information.
Is compounded tirzepatide legal in 2026?
Yes, within limits. Compounding tirzepatide is not banned. What changed is how much compounding is allowed.
During the 2022 to 2024 supply shortage, pharmacies had more room to make copies of the commercial product. On December 19, 2024, the FDA announced the tirzepatide injection shortage was resolved. It then gave compounders a short wind-down period. That period ended for 503A pharmacies on March 5, 2025, after a federal court declined to block the FDA's decision, and for 503B outsourcing facilities on March 19, 2025.
Here is how the rules work now, based on the FDA's April 2026 policy update:
- A prescription for one patient is required. A 503A pharmacy compounds from an individual prescription, not for general sale.
- No routine copies. A pharmacy may not compound products that are "essentially copies" of a commercially available drug regularly or in large amounts. A product with the same active ingredient, a similar strength and the same route (an injection under the skin) is generally treated as a copy.
- The exception is documented clinical need. If the prescriber determines and documents that a specific patient needs a significant difference from the commercial product, such as a dose that is not commercially available or a formulation change for a documented reason, the pharmacy may compound it.
- Outsourcing facilities face tighter limits. On April 30, 2026, the FDA proposed excluding tirzepatide from the list of bulk substances 503B facilities can use, saying it saw no clinical need. That proposal was open for comment through June 2026 and was not final when this guide was updated.
The FDA has also sent warning letters in 2025 and 2026 to telehealth sites and compounders. Common problems were websites that implied the compounded product was FDA-approved or "the same" as the commercial drug, and "clinical need" notes that looked pre-filled rather than written for an individual patient.
💡 What this means for you
A real compounded tirzepatide prescription should come after a genuine medical evaluation, and your prescriber should be able to explain why compounding fits your situation. If a site skips the evaluation or never asks about your health history, treat that as a warning sign.
Safety: what the FDA has said
Tirzepatide itself has well-studied side effects, mainly nausea, diarrhea, vomiting, constipation and stomach pain, especially when the dose goes up. The extra questions with compounded tirzepatide are about quality and dosing.
| FDA concern | What the FDA reported |
|---|---|
| Adverse event reports | More than 730 reports linked to compounded tirzepatide as of May 31, 2026. The FDA says these are likely undercounted because 503A pharmacies do not have to report, and a report does not prove the drug caused the problem. |
| Dosing errors | Reports of adverse events, some needing hospital care, possibly tied to patients measuring the wrong dose and to health care professionals miscalculating doses. |
| Doses beyond the label | Some patients received doses, frequencies or dose-increase schedules beyond those in the FDA-approved label. |
| Shipping temperature | The FDA says not to use any injectable GLP-1 drug that arrives warm or without enough refrigeration. |
| Multi-dose vials | The FDA recommends throwing away a vial 28 days after first use, even if medicine is left, and using a new sterile needle and syringe every time. |
| Fake "research" products | The FDA has warned companies selling tirzepatide labeled "for research purposes" or "not for human consumption" to consumers. These products are of unknown quality. |
Dosing errors are the most preventable risk. Compounded tirzepatide usually comes in a vial, and you draw your dose with a syringe. Vials from different pharmacies can have different strengths, so the amount of liquid for the same mg dose can change. Always follow the instructions on your label, use the syringe your pharmacy supplies, and call the pharmacy if anything does not match. Our guide to needles and syringes for tirzepatide explains why the syringe matters.
Salt forms and added ingredients (B12, niacinamide)
Some compounded GLP-1 products are made with a different chemical form of the drug or with an extra ingredient. Here is what is and is not known.
- Salt forms. The FDA has warned that some compounders use salt forms of semaglutide (such as semaglutide sodium or acetate), which it calls different active ingredients from the approved drug, and says it knows of no lawful basis for compounding with them. The FDA's published salt-form warning names semaglutide. For tirzepatide, ask the pharmacy to confirm the exact active ingredient listed on your label.
- Vitamin B12 or niacinamide. Some pharmacies add vitamin B12 (cyanocobalamin) or niacinamide (a form of vitamin B3). In a September 2026 warning letter, the FDA said tirzepatide and niacinamide products from one large compounder appeared to be essentially copies of the approved product, and that the differences looked pretextual.
- What is not known. We found no FDA statement or clinical trial showing that adding B12 or niacinamide to tirzepatide improves weight loss or reduces side effects. These combinations have not been studied the way tirzepatide alone has.
If an added ingredient is offered, ask your prescriber what it is for and whether you need it.
How it is dosed
Doses should be written in milligrams (mg) and follow the dose steps in the FDA-approved tirzepatide label. The label starts at 2.5 mg once a week for 4 weeks, then increases in 2.5 mg steps no sooner than every 4 weeks, up to a maximum of 15 mg once a week. Many people stay on a lower dose if it works for them.
| Weeks | Weekly dose (FDA label steps) |
|---|---|
| 1 to 4 | 2.5 mg (starting dose) |
| 5 to 8 | 5 mg |
| 9 to 12 | 7.5 mg, if needed |
| 13 to 16 | 10 mg, if needed |
| 17 to 20 | 12.5 mg, if needed |
| 21 and on | 15 mg maximum, if needed |
Your prescriber decides if and when to increase. For more detail, see our tirzepatide dosage guide and when to increase your tirzepatide dose.
How to vet a pharmacy and prescriber
The FDA's BeSafeRx program says a safe online pharmacy always requires a prescription, lists a U.S. physical address and phone number, has a licensed pharmacist to answer questions, and is licensed by a state board of pharmacy. Use this checklist before you order.
Is this compounded tirzepatide source worth trusting?
Check each item before you pay:
✅ Good signs
- A licensed prescriber reviews your health history before prescribing
- The pharmacy is a U.S. pharmacy you can find in your state board's license lookup
- The pharmacy names itself on the label and gives you its phone number
- A pharmacist is available to answer questions
- It ships cold, with ice packs or insulated packaging
- The label shows the strength in mg per mL, a lot number and a beyond-use date
- The pharmacy can tell you how batches are tested for potency and sterility
🚩 Walk away
- "Research use only" or "not for human consumption" on the product
- No prescription or no medical questions required
- Claims it is FDA-approved or the same as a brand-name drug
- Ships from outside the U.S. or arrives warm
- Sells powder you mix yourself without pharmacy instructions
- Prices far below everyone else with no clear explanation
- No pharmacy name, address or lot number on the label
How to check a license. The FDA's BeSafeRx page has a state-by-state pharmacy license lookup. Search the pharmacy's name in your state's board of pharmacy database. The FDA says if the pharmacy is not listed, you should not use it. For an outsourcing facility, you can also check the FDA's list of registered 503B facilities and any inspection reports or warning letters linked there.
About lab testing. Some pharmacies share a certificate of analysis (COA) showing a batch's potency, sterility and endotoxin results. It is fair to ask for one. A COA helps, but it is not an FDA review, and it should match the lot number on your vial.
What compounded tirzepatide costs
There is no single price. Compounded tirzepatide is sold as a monthly program by many telehealth practices and pharmacies, and the price can change with the dose, the length of the plan and what is bundled in. Some programs charge more as the dose goes up.
Before you compare, ask each program these questions:
- Is the price the same at every dose, or does it rise when my dose increases?
- Does the price include the medical visit and follow-up visits?
- Are syringes, alcohol pads and a sharps container included?
- Is cold shipping included?
- Is it a monthly charge or a prepaid multi-month plan, and what is the cancellation or refund policy?
- Which pharmacy fills it, and in which state is it licensed?
For a closer look at monthly pricing, see our compounded tirzepatide monthly cost guide. Compounded tirzepatide is generally not covered by insurance, so plan on paying cash.
The FDA-approved tirzepatide option
Zepbound is the FDA-approved tirzepatide medicine for chronic weight management. Depending on your coverage, it may cost you less than you expect, so check these paths first. Prices below were verified on Lilly's website in October 2026, and Lilly can change them.
| Your situation | Zepbound price path |
|---|---|
| Commercial insurance that covers Zepbound | As little as $25 per fill with the savings card (savings caps apply) |
| Self-pay through LillyDirect, 2.5 mg | $299 per month |
| Self-pay through LillyDirect, 5 mg | $399 per month |
| Self-pay, 7.5 mg to 15 mg | $449 per month with Lilly's offer if refilled within 45 days ($499 to $699 regular price) |
| Medicare | Not eligible for the savings card; Lilly says some may qualify for a Medicare GLP-1 Bridge offer of up to $50 per month |
Zepbound savings cards expire December 31, 2026. If your insurance covers Zepbound, that is very likely your lowest-cost option, so call your plan or ask your doctor to check before paying cash anywhere. See our Zepbound cost by dose guide for more.
Getting treatment through Rx.com
If coverage is not an option for you, Rx.com offers compounded tirzepatide from $149/month on a 12-month plan. That includes an online provider visit, the medication, supplies and cold shipping, at one flat price at every dose, with no insurance needed. A licensed provider reviews your health history to decide whether it is right for you. Compounded medications are not FDA-approved and are not the same as any brand-name medication.
Comparing options? Read our semaglutide vs tirzepatide comparison or the compounded semaglutide safety guide, or start with the short weight-loss eligibility quiz.
🚨 When to Contact Your Healthcare Provider
Call your prescriber, or Poison Control at 1-800-222-1222, if any of these happen. Call 911 for fainting, trouble breathing, or severe pain.
- Severe stomach pain that does not go away, with or without vomiting: possible pancreatitis or gallbladder problems.
- Vomiting or diarrhea that keeps you from drinking fluids: risk of dehydration and kidney strain.
- A lump or swelling in your neck, trouble swallowing or hoarseness.
- Swelling of the face, lips or throat, or a severe rash: possible allergic reaction.
- Redness, warmth or pus at the injection site, or fever: possible infection.
- You think you injected too much, or you are unsure how much to draw: call Poison Control or the pharmacy before your next dose.
Frequently Asked Questions
What is compounded tirzepatide?
It is tirzepatide prepared by a licensed pharmacy for an individual patient with a prescription. It is not FDA-approved and is not the same as any brand-name medication.
Is compounded tirzepatide legal in 2026?
Yes, within limits. The tirzepatide shortage ended in December 2024, but a state-licensed 503A pharmacy may still compound it for an individual patient when the prescriber documents a significant clinical difference that patient needs. Routine copies made in large amounts are not allowed.
Is compounded tirzepatide safe?
It can be used safely with a real prescriber and a licensed pharmacy, but it carries more risk than an FDA-approved product because the FDA does not check its quality before sale. The FDA has received more than 730 adverse event reports linked to compounded tirzepatide, many tied to dosing mistakes.
Does compounded tirzepatide work as well?
The trials that showed up to about 21% average weight loss used the FDA-approved product. Compounded versions have not been tested in those trials, so their results depend on the quality and accuracy of each batch.
What is the difference between 503A and 503B compounding?
A 503A pharmacy is state-licensed and compounds from individual prescriptions. A 503B outsourcing facility registers with the FDA, follows manufacturing standards and is inspected by the FDA, but tirzepatide is not on the list of bulk substances 503B facilities may use.
Is tirzepatide with B12 or niacinamide better?
There is no clinical evidence we could find that these additives improve results. The FDA has said in a 2026 warning letter that some tirzepatide and niacinamide products appeared to be essentially copies of the approved product.
How much does compounded tirzepatide cost?
Prices vary by dose, plan length and what is included. Ask whether visits, supplies and cold shipping are included and whether the price rises with your dose. Rx.com's compounded tirzepatide starts at $149/month on a 12-month plan, one flat price at every dose.
Can I buy compounded tirzepatide without a prescription?
No. Any legitimate source requires a prescription. Products sold without one, or labeled "research use only," are a red flag, and the FDA has warned companies selling them.
How do I know if a pharmacy is licensed?
Use the FDA BeSafeRx state license lookup to search your state board of pharmacy's database. If the pharmacy is not listed, the FDA says not to use it.
Sources
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026). fda.gov
- U.S. Food and Drug Administration. Declaratory order: resolution of shortages of tirzepatide injection products, December 19, 2024. fda.gov
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list, April 30, 2026. fda.gov
- U.S. Food and Drug Administration. Human drug compounding laws (sections 503A and 503B). fda.gov
- U.S. Food and Drug Administration. BeSafeRx: considering an online pharmacy, and locate a state-licensed online pharmacy. fda.gov
- U.S. Food and Drug Administration. Compounding: inspections, recalls, and other actions (registered outsourcing facilities). fda.gov
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. nejm.org
- Tirzepatide injection prescribing information (dosage and administration). DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
- Eli Lilly and Company. Zepbound coverage and savings (accessed October 2026). zepbound.lilly.com
